Nina S. Kjellson Sells 3,993 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 3,993 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total value of $65,325.48. Following the completion of the sale, the director now owns 3,707,420 shares in the company, valued at $60,653,391.20. This represents a 0.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Tyra Biosciences Price Performance

TYRA opened at $15.80 on Thursday. The firm has a market capitalization of $799.48 million, a P/E ratio of -9.81 and a beta of 1.04. Tyra Biosciences, Inc. has a one year low of $12.34 and a one year high of $29.60. The company has a fifty day moving average price of $15.38 and a 200-day moving average price of $19.17.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). On average, analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Wedbush reissued an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research report on Friday, October 25th. Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their target price for the company from $22.00 to $31.00 in a report on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a report on Monday, January 13th. Finally, UBS Group assumed coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They set a “buy” rating and a $28.00 price objective on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $30.50.

Hedge Funds Weigh In On Tyra Biosciences

A number of institutional investors have recently made changes to their positions in TYRA. Janus Henderson Group PLC bought a new stake in shares of Tyra Biosciences during the 3rd quarter worth $24,994,000. Perceptive Advisors LLC raised its position in Tyra Biosciences by 50.5% during the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after purchasing an additional 338,208 shares in the last quarter. Ally Bridge Group NY LLC bought a new stake in Tyra Biosciences during the second quarter worth about $4,232,000. Ensign Peak Advisors Inc purchased a new position in shares of Tyra Biosciences in the 2nd quarter worth about $3,047,000. Finally, American Century Companies Inc. increased its position in shares of Tyra Biosciences by 582.9% during the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock valued at $2,723,000 after purchasing an additional 145,346 shares during the last quarter. Institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.